Drugging the undruggable

Company Details

SyntheX is expanding drug design into the ‘undruggable’ space for the treatment of cancer and rare diseases. We implement an innovative platform for the accelerated discovery of new classes of therapeutics that target the Achilles’ heel of cancer cells in a highly specific and selective manner.

Traditional drugs work by disrupting the enzymatic function of proteins. At SyntheX, we are expanding the drug discovery space from active site inhibitors to protein-protein interaction modulators using our innovative screening technology.

Company People

Maria Soloveychik

Maria Soloveychik
CEO & Co-Founder

Charly Chahwan

Charly Chahwan
CSO & Co-Founder

SyntheX News


You might also be interested in

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities.